[go: up one dir, main page]

MX2009006003A - Composicion que contiene derivados de aurona con fines de diagnostico. - Google Patents

Composicion que contiene derivados de aurona con fines de diagnostico.

Info

Publication number
MX2009006003A
MX2009006003A MX2009006003A MX2009006003A MX2009006003A MX 2009006003 A MX2009006003 A MX 2009006003A MX 2009006003 A MX2009006003 A MX 2009006003A MX 2009006003 A MX2009006003 A MX 2009006003A MX 2009006003 A MX2009006003 A MX 2009006003A
Authority
MX
Mexico
Prior art keywords
sup
diagnosis
amyloid
containing composition
compound
Prior art date
Application number
MX2009006003A
Other languages
English (en)
Inventor
Masahiro Ono
Original Assignee
Univ Nagasaki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nagasaki filed Critical Univ Nagasaki
Publication of MX2009006003A publication Critical patent/MX2009006003A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/0412Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K51/0419Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/36Oxygen atoms in position 3, e.g. adrenochrome

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Furan Compounds (AREA)

Abstract

Una composición para el diagnóstico de una enfermedad relacionada con amiloides, que comprende un compuesto representado por la fórmula general (I): (ver fórmula (I)) en donde X representa O o semejantes; R1, R3, R4, R5, R6, R8 y R9 representan un átomo de hidrógeno o semejantes; R2 representa un átomo de halógeno o semejantes; y R7 representa un grupo dimetilamino o semejantes; o el compuesto marcado con un radionúclido, o una sal farmacéuticamente aceptable del compuesto o del compuesto marcado. El compuesto representado por la fórmula general (I) presenta todas las siguientes propiedades: gran especificidad de unión a la proteína ß-amiloide, gran permeabilidad a través de la barrera hematoencefálica y depuración rápida de los sitios sin placas seniles en el cerebro.A2.
MX2009006003A 2006-12-05 2007-10-26 Composicion que contiene derivados de aurona con fines de diagnostico. MX2009006003A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006328131 2006-12-05
JP2007081602 2007-03-27
PCT/JP2007/070930 WO2008068974A1 (ja) 2006-12-05 2007-10-26 オーロン誘導体含有診断用組成物

Publications (1)

Publication Number Publication Date
MX2009006003A true MX2009006003A (es) 2009-06-17

Family

ID=39491885

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006003A MX2009006003A (es) 2006-12-05 2007-10-26 Composicion que contiene derivados de aurona con fines de diagnostico.

Country Status (11)

Country Link
US (1) US20100003191A1 (es)
EP (1) EP2113258A1 (es)
JP (1) JPWO2008068974A1 (es)
KR (1) KR20090087037A (es)
AU (1) AU2007330190A1 (es)
BR (1) BRPI0719689A2 (es)
CA (1) CA2671596A1 (es)
IL (1) IL198918A0 (es)
MX (1) MX2009006003A (es)
RU (1) RU2009125612A (es)
WO (1) WO2008068974A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193363B2 (en) * 2008-08-29 2012-06-05 Astrazeneca Ab Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits
MX372914B (es) 2015-06-16 2020-04-27 Jiangsu Hengrui Medicine Co Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo.
WO2017180644A1 (en) 2016-04-11 2017-10-19 Middle Tennessee State University Therapeutic aurones
CN117720541A (zh) * 2018-03-09 2024-03-19 里科瑞尔姆Ip控股有限责任公司 取代的1,2-二氢-3H-吡唑并[3,4-d]嘧啶-3-酮
JP7204568B2 (ja) * 2018-04-04 2023-01-16 株式会社Cics アミロイドβ疾患のホウ素中性子捕捉療法用化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0130305D0 (en) * 2001-12-19 2002-02-06 Amersham Plc Compounds for imaging alzheimers disease
CN100537559C (zh) * 2006-06-14 2009-09-09 浙江大学 类黄酮衍生物及其制备方法和用途

Also Published As

Publication number Publication date
WO2008068974A1 (ja) 2008-06-12
CA2671596A1 (en) 2008-12-06
RU2009125612A (ru) 2011-01-20
AU2007330190A1 (en) 2008-06-12
EP2113258A1 (en) 2009-11-04
BRPI0719689A2 (pt) 2013-12-24
US20100003191A1 (en) 2010-01-07
KR20090087037A (ko) 2009-08-14
IL198918A0 (en) 2011-08-01
JPWO2008068974A1 (ja) 2010-03-18

Similar Documents

Publication Publication Date Title
WO2010000372A3 (en) New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
IN2012DN02465A (es)
MY151295A (en) Pyrimidyl indoline compound
TW200728307A (en) Novel spirochromanone derivatives
WO2010136474A3 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
HRP20171175T1 (hr) Novi triciklički spojevi
UA97351C2 (ru) Производная кумарина, имеющая противоопухолевую активность
WO2007138472A3 (en) Triazolopyridazine derivatives
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
UA94052C2 (uk) Похідні піридазину
MX2008014898A (es) Composicion para el diagnostico de enfermedades relacionadas con amiloides.
MX2012000488A (es) Terapia de combinacion para el tratamiento de la diabetes.
WO2011011882A8 (en) Hydroxy fatty acid compounds and uses thereof for disease treatment and diagnosis
UA94606C2 (ru) Производные тиоксантина, композиция, которая их содержит, и их применение в терапии
SG10201806714PA (en) C7-fluoro substituted tetracycline compounds
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
MX2011013648A (es) Nuevos compuestos, composiciones farmaceuticas y metodos relacionados con ellos.
UA93393C2 (uk) 1,3-діоксанкарбонові кислоти
MX2010001020A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.
WO2009095872A3 (en) Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors
MX2008002061A (es) Derivados de tiazolil piperidina utiles como moduladores del receptor h3.
WO2011025982A3 (en) Tetracycline compounds
MX2009006003A (es) Composicion que contiene derivados de aurona con fines de diagnostico.
WO2008132552A3 (en) Omega-3 lipid compounds
IL185410A0 (en) Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in the treatment of parkinson's disease

Legal Events

Date Code Title Description
FA Abandonment or withdrawal